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Background
The mechanisms responsible for the increased thrombotic risk associated with thalassemia
are still unclear. They might be related to the effects of red blood or endothelial cells
derangement, increased numbers of platelets as well as abnormal plasmatic coagulation. 
Design and Methods
To evaluate the relative role played by cells and plasma we investigated 169 patients with
thalassemia by means of thromboelastometry and thrombin generation tests.
Thromboelastometry was taken as an index of the viscoelastic properties of whole blood
after activation of coagulation and is characterized by the clotting time (CT) that may be
considered as a conventional coagulation time; clot formation time (CFT), defined as the
time needed for the clot to reach a fixed firmness and the maximum clot firmness (MCF),
defined as the maximal amplitude of the tracing.
Results
All the thromboelastometry parameters determined in whole blood (including shortened
CT and CFT, and increased MCF), were consistent with hypercoagulability especially in
splenectomized patients. Conversely, thrombin generation as determined in platelet-poor
plasma was not. 
Conclusions
These findings point to blood cells and/or platelets rather than to plasma abnormalities as
the most important determinants of the thrombotic risk observed in thalassemic patients
who had been splenectomized and might have important diagnostic and therapeutic impli-
cations.
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Introduction
Thalassemia is a congenital hemolytic anemia charac-
terized by reduced synthesis of globin chains.1,2 From
the hemostatic stand point it is characterized by hyper-
coagulability and an increased risk of venous and/or
arterial thromboembolism.3+6 However, not all the
patients with thalassemia present with the same risk
and the identification of those at higher risk is not pos-
sible on the basis of the measurements of the individual
components of the hemostatic system nor on the basis
of such global conventional coagulation tests as the pro-
thrombin or activated partial thromboplastin times (PT,
APTT). Failure of these tests to identify hypercoagula-
bility in thalassemia might be due to the absence of
blood cells and platelets which may play a key role in
the mechanisms responsible for thrombosis in this set-
ting. Thromboelastometry, which measures the vis-
coelastic properties of clotting whole blood after activa-
tion of coagulation by such triggers as tissue factor or
partial thromboplastin in combination with calcium
chloride, is in principle a better candidate than the PT
and APTT to assess hypercoagulability in patients with
thalassemia. Such an evaluation is an important prereq-
uisite to the organization of prospective studies aimed
at evaluating the risk of thrombosis in this category of
patients. The study also aims at elucidating the patho-
genesis of hypercoagulability in thalassemia by compar-
ing paired measurements for the same patients per-
formed by means of thromboelastometry in whole
blood versus thrombin generation in plasma.
Design and Methods
Patients 
One-hundred-sixty-nine patients with beta-tha-
lassemia (71males and 98 females with an age spanning
from 19 to 62 years) were enrolled in this study which
was approved by the institutional review board of our
institution. They were consecutive patients referred to
the thalassemia unit for regular clinical visits who on
the occasion of phlebotomy for check up volunteered to
give an additional blood sample for the study. One-hun-
dred-sixteen had thalassemia major and 53 intermedia.
Splenectomized patients were 76/116 (65.6%) and
34/53 (64.2%) for thalassemia major and intermedia,
respectively. None of the patients was on vitamin K
antagonists at the time of blood sampling.
Healthy individuals 
Eighty-six healthy individuals (33 males and 53
females with an age spanning from 23 to 75 years) have
been randomly selected among the population of med-
ical students, the staff of our institution and other vol-
unteers. Exclusion criteria were the presence of splenec-
tomy, known hemorrhagic/thrombotic diseases or
other conditions known to alter the hemostatic balance,
the use of oral anticoagulants or other antithrombotic
drugs, and the use of oral contraceptives. The values
obtained for this population were used to establish ref-
erence intervals for thromboelastometry. Another group
of 154 healthy individuals (71 males, 83 females, ageing
from 17 to 64 years) comparable for age and gender to
the patient population were used as controls for the
thrombin generation assay.
Blood sampling and plasma preparation
After informed consent blood samples from patients
and healthy individuals were collected into vacuum
tubes (BD, Meylan, France) containing 0.109 M sodium
citrate as anticoagulant at a proportion of 9:1
(blood:anticoagulant). One portion of the blood was
used as such for thromboelastometry testing that was
performed within 2 hours from blood collection and the
other was centrifuged at 2880 g for 15 minutes at room
temperature. Supernatant plasma was harvested,
aliquoted in capped plastic tubes, quick frozen in liquid
nitrogen and stored at –70°C for later testing of conven-
tional coagulation parameters and thrombin generation,
performed in batch analyses within 6 months from
blood collection. Blood samples from patients were col-
lected at least three and four weeks after the last blood
transfusion for thalassemia major and intermedia,
respectively. 
Thromboelastometry
Rotation thromboelastometry was performed by
means of the 4 channel ROTEM® Gamma equipment
according to manufacturer instructions and with type
and concentration of reagents (undisclosed) as provided
by the manufacturer (Pentapharm, Munich, Germany).
Among the parameters that were recorded we report on
the following: (i) the Clotting Time (CT), defined as the
time (seconds) from start of the measurement until ini-
tiation of clotting7; (ii) The Clot Formation Time (CFT),
defined as the time (seconds) from initiation of clotting
until a clot firmness of 20 mm is recorded7; (iii)
Maximum Clot Firmness (MCF), defined as the maxi-
mal amplitude (mm) of the tracing obtained after addi-
tion of the hemostatic trigger.7 CT, CFT and MCF were
measured upon triggering hemostasis with reagents
containing partial thromboplastin from rabbit origin,
ellagic acid and calcium chloride (INTEM®,
Pentapharm) or with reagents containing tissue factor
and calcium chloride (EXTEM®, Pentapharm). INTEM
and EXTEM are considered to reflect the intrinsic or
extrinsic activation of hemostasis. All the measure-
ments were taken on citrated blood according to manu-
facturer’s instructions. Samples from patients and
healthy individuals were handled in the same manner
and within the same time frame.
Thrombin generation
Thrombin generation was assessed on thawed plas-
ma in batch analyses within 6 months from blood col-
lection. To minimize analytical variability equal num-
bers of plasmas from patients and controls were includ-
ed at each test occasion. Thrombin generation was
assessed as Endogenous Thrombin Potential (ETP)
according to Hemker and coworkers8 as described in
details by Chantarangkul et al.9 Briefly, the test is based
on the activation of coagulation in platelet-poor plasma
A. Tripodi et al.
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after addition of human relipidated recombinant tissue
factor (Recombiplastin, Instrumentation Laboratory) in
the presence of the synthetic phospholipids 1,2-
dioleoyl-sn-glycero-3-phosphoserine (DOPS), 1,2-
dioleoyl-sn-glycero-3-phosphoetanolamine (DOPE) and
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC)
(Avanti Polar Lipids Inc., Alabaster, AL, USA) in the pro-
portion of 20/20/60 (M/M). The concentrations of tissue
factor and phospholipids in the test system were 1 pM
and 1.0 mM, respectively. Testing for ETP was per-
formed in the presence of soluble rabbit thrombomod-
ulin (ICN Biomedicals, Aurora, Ohio) added to the reac-
tion mixture at a final concentration of 4 nM.
Continuous registration of the generated thrombin was
achieved with a fluorogenic synthetic substrate (Z-Gly-
Gly-Arg-AMC HCl, Bachem, Switzerland) added to the
test system at a final concentration of 417 µM. The pro-
cedure was carried out with an automated fluorometer
(Fluoroskan Ascent, ThermoLabsystem, Helsinki,
Finland). Readings from the fluorometer were automat-
ically recorded and calculated by a dedicated software
(ThrombinoscopeTM, Thrombinoscope BV, Maastricht,
The Netherlands ), which displays thrombin generation
curves [nM thrombin versus time (minute)] and calcu-
lates the area under the curve, defined as ETP and
expressed as nM thrombin times minutes (nM*min).
Thrombin generation is measured as function of an
internal calibrator for thrombin (Thrombin Calibrator,
Thrombinoscope BV). ETP represents the plasmatic bal-
ance between the action of pro-coagulants and anti-
coagulants.
Conventional coagulation parameters and blood cells
counts
The following parameters were measured on thawed
plasmas at the end of the study and no later than 10
months from the beginning of the enrolment. PT and
APTT with results expressed as ratio (patient-to-normal
coagulation time) by means of a human recombinant
relipidated thromboplastin (Recombiplastin,
Instrumentation Laboratory, Orangeburg, NY) or the
automated APTT (bioMerieux, Durham, NC);
antithrombin as heparin co-factor activity with
Electrachrome Antithrombin (Instrumentation
Laboratory); protein C as anticoagulant activity (PC clot,
Instrumentation Laboratory); factors II, VIII and V by
one-stage coagulation assays. Results for antithrombin,
factors II, VIII and V were expressed as % of a reference
frozen plasma prepared by mixing equal volumes of
plasmas obtained from blood of 30 healthy individuals
and arbitrarily set at 100% activity. Fibrinogen (mg/dL)
was measured by means of a functional thrombin-based
coagulation assay as clottable protein (Q.F.A. Thrombin,
Instrumentation Laboratory). Complete blood cells
counts were performed with an automated device (ABX
Micros 60, ABX International, Montpellier, France).
Data analyses
Results are presented as medians and ranges (min-
max values). The Mann-Whitney, Kruskal Wallis and
the Spearman rho correlation tests were used as appro-
priate. p values of less than 0.05 were considered as sta-
tistically significant. For the purpose of this study refer-
ence intervals were determined as the values below the
5th (CT and CFT) or above the 95th (MCF) percentiles of
distribution of results for healthy individuals. The per-
centage of patients whose results fell outside the rele-
vant cut-off values for the various categories investigat-
ed were compared by the Pearson Chi square test. All
analyses were performed with the SPSS version 17.0
software (Chicago, IL, USA).
Results
Conventional coagulation parameters and blood
counts for the population of thalassemic patients are
reported in Table 1. Platelets and leucocytes numbers
and factor VIII activity for patients who had been
splenectomized were significantly greater than those
who had not, both for thalassemia major and interme-
dia. Factor V activity was significantly greater for
splenectomized than for non-splenectomized patients
with thalassemia major. Antithrombin activity was sig-
nificantly lower for splenectomized than for non-
splenectomized patients with thalassemia intermedia.
Finally, the comparison of thalassemia major vs. inter-
media revealed a significant difference only for protein
C activity (mean 63%, range 16-124% vs. 72%, 35-
129%) (p<0.05). 
Thromboelastometry 
The distributions of results for thromboelastometry
parameters are shown in Fig 1 (panels A-C) and Table 2,
and the percentage of patients with abnormal values are
shown in Fig.s 1A-1C and 2). In general, there were neg-
ligible differences within each parameter regardless of
whether it was determined as INTEM or EXTEM;
therefore, results for each parameter are shown as
INTEM.
Clotting time (CT)
Overall, CT values were not significantly different
between thalassemia major (median 159 sec, range 110-
220) and intermedia (163 sec, 116-213) (p=0.34).
However, within both groups values for splenec-
tomized patients were significantly shorter than those
recorded for non-splenectomized patients [major, 157
sec (110-220) vs. 176 sec (135-200), p=0.005; intermedia
159 sec (117-210) vs. 178 sec (149-213), p<0.001] (Figure
1A and Table 2). Overall, the percentage of patients
with abnormally shortened CT values (i.e., below the
5th percentile of the healthy population) was 25% for
thalassemia major and 20.8% for intermedia. Within
both types of thalassemia, the percentage of abnormal
CT values was relatively greater for those patients who
had been splenectomized than those who had not
[major=28.9% vs. 17.5%, p=0.18; intermedia=32.4% vs.
0%, p=0.005) (Figures 1A and 2).
Clot formation time (CFT)
Overall, CFT values were not significantly different
between thalassemia major (61 sec, 33-236) and inter-
media (66 sec, 30-204), (p=0.11). However, within both
Thalassemia and hypercoagulability 
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groups, values for splenectomized patients were signifi-
cantly shorter than those for non-splenectomized
patients [major, 52 sec (33-88) vs. 85 sec (56-236),
p<0.001; intermedia 60 sec (30-87) vs. 116 sec (50-204),
p<0.001] (Figure 1B and Table 2). Overall, the percent-
age of patients with abnormally shortened CFT values
(i.e., below the 5th percentile of the healthy population)
was 29.3% for thalassemia major and 24.5% for inter-
media. Within both types of thalassemia, the percent-
age of abnormal CFT values was significantly greater for
those patients who had been splenectomized than
those who had not [major=44.7% vs. 0%, p<0.001;
intermedia = 35.3% vs. 5.3%, p=0.01) (Figures 1B and
2).
Maximum clot firmness (MCF)
Overall, MCF values were not significantly different
between thalassemia major (64 mm, 43-81) and inter-
media (66 mm, 45-80) (p=0.75). However, within both
groups values for splenectomized patients were signifi-
cantly greater than those recorded for non-splenec-
tomized patients [major, 66 mm (55-81) vs. 59 mm (43-
70), p<0.001; intermedia 68 mm (60-80) vs. 56 mm (45-
71), p<0.001] (Figure 1C and Table 2). Overall, the per-
centage of patients with abnormally increased MCF
value (i.e., above the 95th percentile of the healthy pop-
ulation) was 25.9% for thalassemia major and 32.1%
for intermedia. Within both types of thalassemia, the
percentage of abnormal MCF values was significantly
greater for those patients who had been splenectomized
than those who had not [major=38.2% vs. 2.5%,
A. Tripodi et al.
| 4 | haematologica | 2009; 94(11)
Table 1. Values [median (range, min-max)] of conventional coagulation parameters and blood counts for patients with thalassemia. 
Parameter Thalassemia Major Thalassemia Intermedia
Splenectomy Total Splenectomy Total
Yes No Yes No
PT* 0.98 0.98 0.98 0.98 0.97 0.97
(Reference  (0.74-1.28) (0.73-1.18) (0.73-1.28) (0.78-1.11) (0.74-1.06) (0.74-1.11)
range: 0.90-1.15)
APTT* 1.07a 1.16a 1.10 1.06 1.11 1.07
(Reference  (0.68-1.59) (0.87-1.39) (0.68-1.59) (0.79-1.29) (0.93-1.32) (0.79-1.32)
range: 0.90-1.15)
Platelets x109/L 574a 289a 440 651b 159b 543
(202-1,169) (76-421) (76-1,169) (339-1,121) (72-376) (72-1,121)
Erythrocytes x1012/L 3.5 3.4 3.5c 3.6b 4.5b 3.9c
(2.6-4.3) (3.0-4.3) (2.6-4.4) (2.8-5.0) (2.5-6.4) (2.5-6.4)
Leucocytes x109/L 13.2a 6.8a 10.5 13.5b 6.8b 10.2
(6.0-28.4) (2.7-11.0) (2.7-28.4) (5.5-18.0) (3.4-9.8) (3.4-18.0)
Factor II# 77 77 77 75 81 79
(Reference  (29-100) (48-104) (29-104) (49-103) (22-121) (22-121)
range: 60-120)
Factor V# 97a 80a 91 97 92 95
(Reference (56-138) (38-128) (38-138) (42-149) (56-147) (42-149)
range: 60-120)
Factor VIII# 124a 107a 118 121b 95b 117
(Reference  (58-248) (69-199) (58-248) (86-274) (59-200) (59-274)
range: 60-130)
Fibrinogen 256 230 248 240 281 251
mg/dL (143-410) (136-417) (136-417) (139-653) (166-691) (139-691)
(Reference  
range: 100-350)
Antithrombin# 85 88 85 81b 94b 85
(Reference (36-115) (52-119) (36-119) (68-116) (69-123) (68-123)
range: 80-120)
Protein C# 63 63 63c 72 77 72c
(Reference (16-124) (33-95) (16-124) (42-93) (35-129) (35-129)
range: 60-120)
*ratio of patient-to-normal coagulation times; #% of the pooled normal plasma; ap<0.05 splenectomy yes vs.no (thalassemia major); bp<0.05 splenectomy yes vs.no (tha-
lassemia intermedia); cp<0.05 thalassemia major vs. intermedia.©F
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p<0.001; intermedia=47.1% vs. 5.3%, p=0.002) (Figures
1C and 2).
Other thromboelastometry parameters. Other param-
eters of thromboelastometry such as the time to MCF,
alpha angle, maximum velocity, time to maximum
velocity and area under the tracing were all consistent
with hypercoagulability with statistically significant dif-
ferences for splenectomized versus non-splenectomized
patients (data not shown).
Thrombin generation
The distribution of ETP values is shown in Figure 3.
Patients with either type of thalassemia obtained ETP
values not significantly different from those of healthy
individuals. Furthermore, within both groups of tha-
lassemia there were no significant differences between
those patients who had been splenectomized and those
who had not, although the median values for the former
tended to be greater than those recorded for the latter.
Discussion
It is widely recognized that patients with thalassemia
are at increased risk of venous and/or arterial thrombo-
sis. A recent survey, carried out in the Mediterranean
area and Iran among 8,860 patients, estimated the
cumulative prevalence of thromboembolic events at
1.65%, with thromboses occurring 4.38 times more fre-
quently in patients with thalassemia intermedia than
major.10 Interestingly, venous thromboembolism has
been recorded more frequently than arterial throm-
boembolism (stroke) both for patients with thalassemia
major (48% vs. 28%) or intermedia (66% vs. 9%).10
Furthermore, the risk was greater for patients who had
Thalassemia and hypercoagulability 
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Figure 1. Values of thromboelastometry parameters as measured
in patients with thalassemia. Panel A, Clotting time (CT); panel B,
Clot formation time (CFT); panel C, maximum clot firmness (MCF).
Horizontal bars represent median values. Shaded areas represent
the 5th percentile of the distribution of the reference population for
CT and CFT, and the 95th percentile for MCF. Numbers on the bot-
tom represent the proportions of patients identified as having val-
ues of thromboelastometry parameters below the 5th (for CT and
CFT) or above the 95th percentile (for MCF).
Table 2. Values [median (range, min-max)] of thromboelastometry parameters for patients with thalassemia.
Parameter Thalassemia Major Thalassemia  Intermedia
Splenectomy Splenectomy Total Splenectomy Splenectomy Total
yes no Yes no
CT
(cut-off 157b 176b 159a 159c 178c 163a
value: <148 sec) (110-220) (135-200) (110-220) (117-210) (149-213) (117-213)
CFT
(cut-off 52c 85c 61a 60c 116c 66a
value: <50 sec) (33-88) (56-236) (33-236) (30-87) (50-204) (30-204)
MCF
(cut-off 66c 59c 64a 68c 56c 66a
value: >68 mm) (55-81) (43-70) (43-81) (60-80) (45-71) (45-80)
ap: N.S.; bp: 0.005; cp <0.001.
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been splenectomized than for those who had not.10
Other risk factors of thrombosis, especially in patients
with thalassemia intermedia, may be older age (>20
years), previous thromboembolic events and family his-
tory. The mechanisms underlying hypercoagulability
and the increased thrombotic risk associated with tha-
lassemia are still unclear. They might be explained by
the combined effects of the endothelial and red blood
cells derangement, the first occurring as a consequence
of the ongoing inflammatory state consequent to the
disease and the second as a consequence of the oxida-
tive stress and/or exposure of negatively-charged phos-
pholipids (phosphatidylserine) on cell membranes that
are able to accelerate the conversion of prothrombin to
thrombin.11,12 Although a number of reports identified
abnormal coagulation (assessed by the measurement of
individual hemostatic components, either pro- or anti-
coagulants), or increased numbers of platelets as an
additional cause for thrombosis6,13 other laboratory
parameters, including genetic factors predisposing to
thrombosis,14 failed to identify patients at increased risk.
We reasoned that such failure might be due to the fact
that conventional tests do not truly represent the bal-
ance of coagulation as it occurs in vivo in these patients.
As a matter of fact, conventional tests for pro- and anti-
coagulant factors have been designed to be performed
on plasma, thus missing the contributory effect that
platelets, leucocytes and red blood cells may have on
the hemostatic unbalance leading to thrombosis. 
To test this hypothesis we investigated citrated whole
blood from a large cohort of thalassemic patients by
thromboelastometry that can be considered as a global
test for hemostasis. We also sought to investigate
platelet poor plasmas from the same patients by means
of a thrombin generation assay where coagulation acti-
vation is attained by small amounts of tissue factor as
trigger, phospholipids as platelet substitutes and throm-
bomodulin as the activator of the endogenous protein C
anticoagulant system. This is a global test defined by
the area under the thrombin generation curve (i.e,
thrombin concentration versus time) called endogenous
thrombin potential (ETP). The ETP can be considered as
a reliable index of the amount of thrombin that any
given plasma may generate under the specified experi-
mental conditions and represents the balance between
the pro- and anti-coagulant proteins operating in plas-
ma. The test as modified by the addition of thrombo-
modulin mimics more closely than any other plasma
test what occurs in vivo. It can be useful to assess hypo-
and hyper-coagulability15,16 and the risk of the occur-
rence and recurrence of venous thromboembolism.17,
18
This study shows that conventional parameters of
blood coagulation in our cohort were near normal,
except protein C and factor II that in thalassemia major
were close to the lower limits of their respective refer-
ence intervals (Table 1). There were, however, signifi-
cantly greater activities of factors V and VIII and greater
numbers of platelets and leucocytes for patients who
had been splenectomized compared to those who had
not (see Table 1). On one hand, these findings confirm
previous information suggesting that elevated platelets
and leucocytes may be risk factors for thrombosis in
splenectomized patients; numbers of platelets were,
indeed, significantly correlated (p<0.001) with the three
parameters of thromboelastometry (ρ values -0.28; -0.65
and 0.63 for CT, CFT and MCF, respectively), but on the
other indicate that conventional coagulation parameters
are of little value to assess the risk of thrombosis in this
category of patients with the possible exception of fac-
tor VIII. Elevated levels of factor VIII had, in fact, been
associated with an increased risk of occurrence and
recurrence of venous thromboembolism in throm-
bophilic patients19 and might, therefore, play some role
also in splenectomized thalassemic patients.
This study also shows for the first time that patients
with thalassemia had abnormalities for all the throm-
A. Tripodi et al.
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Figure 2. Percentage of patients identified as having values of
thromboelastometry parameters below the 5th (for CT and CFT) or
above the 95th percentile (for MCF). Solid and open columns rep-
resent splenectomized or non-splenectomized patients.
Figure 3. Box plots showing distribution (median, lower and upper
quartiles) of ETP values for healthy individuals and patients with
thalassemia.
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boelastometry parameters suggestive of hypercoagula-
bility. Median CT and CFT values were significantly
smaller and median MCF values were greater for
patients who had been splenectomized compared to
those who had not (see Fig.s 1A-C). Furthermore, the
rate of abnormal values for the three parameters was
significantly greater for those patients who had been
splenectomized compared to those who had not (see
Figures 1A-C and 2). CT may be considered as a con-
ventional coagulation time and was, in fact, correlated
with the APTT ratio (rho=0.52, p<0.001). Since short-
ened APTT has been associated with an increased risk
of occurrence20 and recurrence21,22 of venous throm-
boembolism in thrombophilic patients, it is not surpris-
ing that shortened CT detects hypercoagulability in
splenectomized thalassemia patients. CFT is defined as
the time needed for the clot to reach a fixed firmness (20
mm) and MCF as the maximal amplitude of the tracing
after the addition of the trigger. Accordingly, shortened
CFT and increased MCF can be considered as indexes of
hypercoagulability. These findings are in line with the
clinical evidence that splenectomized thalassemic
patients are at increased risk of thrombosis and suggest
thromboelastometry as a potential candidate to assess
the risk of thrombosis in this category of patients.
Although the retrospective nature of this study did not
allow assessing the predictive value of thromboelastom-
etry parameters for thrombosis, our findings pave the
way to prospective studies based on CT, CFT and MCF
that may substantiate our hypothesis.
Another important and new finding of this study is
that thrombin generation assessed as ETP in platelet-
poor plasma from thalassemic patients is normal and
there are no differences between values recorded for
patients who had been splenectomized compared to
those who had not (Figure 3). Thrombin generation has
been evaluated in plasma without the addition of corn
trypsin inhibitor that quenches undesirable contact acti-
vation. This may be regarded as a limitation of our
study. However, it is unlikely that the effect of contact
activation on thrombin generation was different in the
two populations of patients with or without splenecto-
my. The information on normal thrombin generation if
compared to the thromboelastometry findings might
have important implications. First, it demonstrates that
the risk of thrombosis in thalassemic patients is mediat-
ed by platelets, leucocytes, abnormal red blood and/or
damaged endothelial cells, rather than by plasma abnor-
malities, thus substantiating and extending previous
evidence from the literature.10 It is well established that
activated platelets play a crucial role in thrombin gener-
ation.23 In addition, platelets from thalassemic patients
present with increased adhesion under flow condi-
tions,24 presumably due to oxidative stress with the gen-
eration of reactive oxygen species.25 However, it is
unknown whether this increased adhesiveness corre-
sponds to an increased procoagulant activity.
Unfortunately, ETP in platelet-rich plasma could not be
measured due to shortage of samples. Therefore, we
could not assess whether the increased numbers of
platelets are more implicated in the thrombotic process
than abnormal red blood or damaged endothelial cells.
Second, if one assumes that plasma is not implicated in
the thrombotic process, then vitamin K antagonists,
which are the drugs of choice to prevent recurrence of
venous thromboembolism,26 might be inappropriate for
patients with thalassemia. Aspirin, on the other hand,
has not yet been investigated for its effectiveness in pre-
venting the occurrence (recurrence) of venous throm-
boembolism in the general population of thrombophilic
patients and there is no evidence on its effectiveness in
thalassemic patients. Perhaps, alternative approaches
could be the reduction of the numbers of red blood cells
exhibiting pro-coagulant activity in splenectomized
patients by regular transfusions or the correction of the
red blood cell abnormalities induced by reactive oxygen
species by administration of antioxidants.27 Clinical
studies are warranted to investigate this issue.
In conclusion, this study shows that all the thromboe-
lastometry parameters determined in whole blood are
compatible with the hypercoagulability in splenec-
tomized thalassemic patients. Conversely, thrombin
generation determined in platelet-poor plasma is not.
These findings point to the blood, endothelial cells
and/or platelets rather than to plasmatic abnormalities
as the most important determinants of the thrombotic
risk observed in this category of patients and might
have important diagnostic and therapeutic implications.
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